

**BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Accusation Against:

**UNICARE PHARMACY, INC. DBA
MEDICORX SPECIALTY
7039 Valjean Avenue
Van Nuys, CA 91406
Original Permit No. PHY 50336,**

**VLADIMIR LENCHITSKY
3514 Cody Road
Sherman Oaks, CA 91403
Pharmacist License No. RPH 51484,**

and

**MICHAEL J. STERLING
7 Hacienda Road
Bell Canyon, CA 91307
Pharmacist License No. RPH 36628**

Respondents.

Case No. 5622

OAH No. 2016090587

DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on June 12, 2017.

It is so ORDERED on May 12, 2017.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA



By

Amy Gutierrez, Pharm.D.
Board President

1 XAVIER BECERRA
Attorney General of California
2 THOMAS L. RINALDI
Supervising Deputy Attorney General
3 EMILY Y. WADA
Deputy Attorney General
4 State Bar No. 241845
300 So. Spring Street, Suite 1702
5 Los Angeles, CA 90013
Telephone: (213) 897-8944
6 Facsimile: (213) 897-2804
Attorneys for Complainant
7

8 **BEFORE THE**
BOARD OF PHARMACY
9 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA

10 In the Matter of the Accusation Against:

11 **UNICARE PHARMACY, INC. DBA**
12 **MEDICORX SPECIALTY**
13 **7039 Valjean Avenue**
14 **Van Nuys, CA 91406**
Original Permit No. PHY 50336,

15 **VLADIMIR LENCHITSKY**
16 **3514 Cody Road**
Sherman Oaks, CA 91403
Pharmacist License No. RPH 51484,

17 and

18 **MICHAEL J. STERLING**
19 **7 Hacienda Road**
Bell Canyon, CA 91307
20 **Pharmacist License No. RPH 36628**

21 Respondents.

Case No. 5622

OAH No. 2016090587

STIPULATED SETTLEMENT OF:

(1) WITHDRAWAL OF ACCUSATION
AND ISSUANCE OF CITATION AS TO
RESPONDENT UNICARE PHARMACY,
INC., DBA MEDICORX SPECIALTY,
AND

(2) DISCIPLINARY ORDER FOR
PUBLIC REPROVAL AS TO
RESPONDENTS LENCHITSKY AND
STERLING

[Bus. & Prof. Code § 495]

22 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
23 entitled proceedings that the following matters are true:

24 ///

25 ///

26 ///

27 ///

28 ///

1 PARTIES

2 1. Virginia Herold (“Complainant”) is the Executive Officer of the Board of Pharmacy
3 (“Board”). She brought this action solely in her official capacity and is represented in this matter
4 by Xavier Becerra, Attorney General of the State of California, by Emily Y. Wada, Deputy
5 Attorney General.

6 2. Respondent Unicare Pharmacy, Inc. dba Medicorx Specialty, Vladimer Lenchitsky,
7 and Michael J. Sterling (“Respondents”) are represented in this proceeding by attorney Noah E.
8 Jussim Esq., whose address is: 11601 Wilshire Blvd., Suite 800, Los Angeles, CA 90025.

9 JURISDICTION

10 3. On or about July 14, 2010, the Board issued Original Permit No. PHY 50336 to
11 Unicare Pharmacy, Inc., dba Medicorx Specialty (“Respondent Unicare”). Vladimir Lenchitsky
12 owns 60% of the corporation’s shares and is its President. He was also its Pharmacist-in-Charge
13 from July 14, 2010 to September 23, 2013. Sofia Kravchinsky owns 40% of its shares and is its
14 Vice President. From September 23, 2013 to the present, Michael Sterling has been its
15 Pharmacist-in-Charge. The Original Permit was in full force and effect at all times relevant to the
16 charges brought in Accusation No. 5622 and will expire on July 1, 2017, unless renewed.

17 4. On or about March 28, 2000, the Board of Pharmacy issued Pharmacist License
18 Number RPH 51484 to Vladimir Lenchitsky (“Respondent Lenchitsky”). The license was in
19 force and at all times alleged in this Accusation and will expire on February 29, 2018, unless
20 renewed.

21 5. On or about August 20, 1981, the Board of Pharmacy issued Pharmacist License
22 Number RPH 36628 to Michael J. Sterling (“Respondent Sterling”). The license was in force and
23 at all times alleged in this Accusation and will expire on March 31, 2017, unless renewed.

24 6. Accusation No. 5622 was filed before the Board of Pharmacy, Department of
25 Consumer Affairs and is currently pending against Respondent. The Accusation and all other
26 statutorily required documents were properly served on Respondent on March 24, 2016.
27 Respondent timely filed its Notice of Defense contesting the Accusation. A copy of Accusation
28 No. 5622 is attached as exhibit A and incorporated herein by reference.

ADVISEMENT AND WAIVERS

1
2 7. Respondents have carefully read, fully discussed with counsel, and understand the
3 charges and allegations in Accusation No. 5622. Respondents have also carefully read, fully
4 discussed with counsel, and understand the effects of this Stipulated Settlement of: (1) Citation
5 and Fine as to Respondent Unicare Pharmacy, Inc., dba Medicorx Specialty, and (2) Disciplinary
6 Order for Public Reproval as to Respondents Vladimer Lenchitsky and Michael J. Sterling
7 (“Stipulated Settlement”).

8 8. Respondents are fully aware of their legal rights in this matter, including the right to a
9 hearing on the charges and allegations in the Accusation; the right to be represented by counsel at
10 its own expense; the right to confront and cross-examine the witnesses against them; the right to
11 present evidence and to testify on its own behalf; the right to the issuance of subpoenas to compel
12 the attendance of witnesses and the production of documents; the right to reconsideration and
13 court review of an adverse decision; and all other rights accorded by the California
14 Administrative Procedure Act and other applicable laws.

15 9. Respondents voluntarily, knowingly, and intelligently waive and give up each and
16 every right set forth above.

CULPABILITY

17
18 10. Respondents understand and agree that the charges and allegations in Accusation No.
19 5622, if proven at a hearing, constitute cause for imposing discipline upon their permit and
20 licenses.

21 11. For the purpose of resolving the Accusation without the expense and uncertainty of
22 further proceedings, Respondents agree that, at a hearing, Complainant could establish a factual
23 basis for the charges in the Accusation, and that Respondents hereby give up their right to contest
24 those charges.

25 12. Respondents agree that their permit and licenses are subject to discipline and they agree
26 to be bound by the Order below.

27 ///

28 ///

CONTINGENCY

1
2 13. This stipulation shall be subject to approval by the Board of Pharmacy. Respondents
3 understand and agree that counsel for Complainant and the staff of the Board of Pharmacy may
4 communicate directly with the Board regarding this stipulation and settlement, without notice to
5 or participation by Respondents or their counsel. By signing the stipulation, Respondents
6 understand and agree that they may not withdraw its agreement or seek to rescind the stipulation
7 prior to the time the Board considers and acts upon it. If the Board fails to adopt this stipulation
8 as its Decision and Order, the Stipulated Settlement shall be of no force or effect, except for this
9 paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not
10 be disqualified from further action by having considered this matter.

11 14. The parties understand and agree that Portable Document Format (PDF) and facsimile
12 copies of this Stipulated Settlement, including Portable Document Format (PDF) and facsimile
13 signatures thereto, shall have the same force and effect as the originals.

14 15. This Stipulated Settlement is intended by the parties to be an integrated writing
15 representing the complete, final, and exclusive embodiment of their agreement. It supersedes any
16 and all prior or contemporaneous agreements, understandings, discussions, negotiations, and
17 commitments (written or oral). This Stipulated Settlement may not be altered, amended,
18 modified, supplemented, or otherwise changed except by a writing executed by an authorized
19 representative of each of the parties.

20 16. In consideration of the foregoing admissions and stipulations, the parties agree that
21 the Board may, without further notice or formal proceeding, issue and enter the following Order:

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///

1 ORDER

2 IT IS HEREBY ORDERED that:

3 1. Complainant shall withdraw the pending accusation and, in place of the accusation,
4 issue a citation to Respondent Unicare Pharmacy, Inc., dba Medicorx Specialty, Original Permit
5 No. PHY 50336, under Business and Professions Code section 125.9 on the following terms.

6 a. Respondent Unicare shall be cited for violation of Business and Professions
7 Code section 4301, subdivision (o), in conjunction with Health and Safety Code sections 111340,
8 subdivision (b), and section 111440;

9 b. The citation shall charge that the violations occurred on or about March 10,
10 2015, in Van Nuys, California, regarding the maintenance and use of medication stock bottles;

11 c. The citation shall carry an administrative fine of \$5,000.00 due 30 days after
12 the citation's issuance;

13 d. Payment of the fine shall not constitute an admission of the violations charged;
14 and,

15 e. Respondent Unicare shall not appeal or contest the citation.

16 2. Pharmacist License Number RPH 51484 issued to Respondent Vladimir Lenchitsky
17 shall be publicly reprovved by the Board of Pharmacy under Business and Professions Code
18 section 495 in resolution of Accusation No. 5622, attached as Exhibit A. The letter shall be in
19 substantially the same form as the letter attached hereto as Exhibit B. In addition, Respondent
20 Lenchitsky further agrees to the following:

21 a. Respondent Lenchitsky will not serve as a pharmacist-in-charge of any
22 pharmacy for a period of two years from the effective date of the decision to adopt this Stipulated
23 Settlement;

24 b. Respondent Lenchitsky will complete ten (10) hours of remedial education
25 within two years from the effective date of the decision to adopt this Stipulated Settlement; and,

26 c. Respondent Lenchitsky will complete an ethics course, approved in advance by
27 the Board of its designee, within two years from the effective date of the decision to adopt this
28

1 Stipulated Settlement, and submit a certificate of completion to the Board or its designee within
2 five days after completing the course.

3 3. Pharmacist License Number RPH 36628 issued to Michael J. Sterling shall be
4 publicly reprovod by the Board of Pharmacy under Business and Professions Code section 495 in
5 resolution of Accusation No. 5622, attached as Exhibit A. The letter shall be in substantially the
6 same form as the letter attached hereto as Exhibit B. In addition, Respondent Sterling further
7 agrees to the following:

8 a. Respondent Sterling will not serve as a pharmacist-in-charge, designated
9 representative-in-charge, or owner of any pharmacy for a period of two years from the effective
10 date of the decision to adopt this Stipulated Settlement; and,

11 b. Respondent Sterling will complete an ethics course, approved in advance by the
12 Board of its designee, within two years from the effective date of the decision to adopt this
13 Stipulated Settlement, and submit a certificate of completion to the Board or its designee within
14 five days after completing the course.

15 4. **Cost Recovery.** Respondents Lenchitsky and Sterling shall pay \$13,172.00 to the
16 Board for its costs associated with the investigation and enforcement of this matter. Respondents
17 Lenchitsky and Sterling shall be jointly and severally liable for the payment of these costs.
18 Respondents Lenchitsky and Sterling shall be permitted to pay these costs in a payment plan
19 approved by the Board. If Respondents Lenchitsky and Sterling fail to pay the Board costs as
20 ordered, Respondents shall not be allowed to renew their pharmacists licenses until Respondents
21 pays costs in full.

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

ACCEPTANCE

I have carefully read the above Stipulated Settlement of: (1) Citation and Fine as to Respondent Unicare Pharmacy, Inc., dba Medicorx Specialty, and (2) Disciplinary Order for Public Repeval as to Respondents Vladimer Lenchitsky and Michael J. Sterling, and have fully discussed it with my attorney, Noah E. Jussim Esq. I understand the stipulation and the effect it will have on my original permit and pharmacist licenses. I enter into this Stipulated Settlement voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Board of Pharmacy.

DATED: 03/27/2017

Vladimir Lenchitsky

UNICARE PHARMACY, INC. DBA MEDICORX
SPECIALTY, VLADIMER LENCHITSKY, SOFIA
KRAVSCHINSKY
Respondent

DATED: 03/27/2017

Vladimir Lenchitsky

VLADIMER LENCHITSKY
Respondent

DATED: _____

MICHAEL J. STERLING
Respondent

I have read and fully discussed with Respondents Unicare Pharmacy, Inc., dba Medicorx Specialty, Vladimer Lenchitsky, and Michael J. Sterling the terms and conditions and other matters contained in the above Stipulated Settlement of: (1) Citation and Fine as to Respondent Unicare Pharmacy, Inc., dba Medicorx Specialty, and (2) Disciplinary Order for Public Repeval as to Respondents Vladimer Lenchitsky and Michael J. Sterling. I approve its form and content.

DATED: 3/27/17

N/E
NOAH E. JUSSIM ESQ.
Attorney for Respondent

///

ACCEPTANCE

I have carefully read the above Stipulated Settlement of: (1) Citation and Fine as to Respondent Unicare Pharmacy, Inc., dba Medicorx Specialty, and (2) Disciplinary Order for Public Repeval as to Respondents Vladimir Lenchitsky and Michael J. Sterling, and have fully discussed it with my attorney, Noah E. Jussim Esq. I understand the stipulation and the effect it will have on my original permit and pharmacist licenses. I enter into this Stipulated Settlement voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Board of Pharmacy.

DATED: _____

UNICARE PHARMACY, INC. DBA MEDICORX
SPECIALTY, VLADIMIR LENCHITSKY, SOFIA
KRAVSCHINSKY
Respondent

DATED: _____

VLADIMIR LENCHITSKY
Respondent

DATED: March 27, 2017

Michael J. Sterling
MICHAEL J. STERLING
Respondent

I have read and fully discussed with Respondents Unicare Pharmacy, Inc., dba Medicorx Specialty, Vladimir Lenchitsky, and Michael J. Sterling the terms and conditions and other matters contained in the above Stipulated Settlement of: (1) Citation and Fine as to Respondent Unicare Pharmacy, Inc., dba Medicorx Specialty, and (2) Disciplinary Order for Public Repeval as to Respondents Vladimir Lenchitsky and Michael J. Sterling. I approve its form and content.

DATED: 3/27/17

Noah E. Jussim
NOAH E. JUSSIM ESQ.
Attorney for Respondent

///



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

ENDORSEMENT


The foregoing Stipulated Settlement of: (1) Citation and Fine as to Respondent Unicare Pharmacy, Inc., dba Medicorx Specialty, and (2) Disciplinary Order for Public Repeval as to Respondents Vladimer Lenchitsky and Michael J. Sterling, is hereby respectfully submitted for consideration by the Board of Pharmacy of the Department of Consumer Affairs.

Dated:

March 27, 2017

Respectfully submitted,

XAVIER BECERRA
Attorney General of California
THOMAS L. RINALDI
Supervising Deputy Attorney General


EMILY Y. WADA
Deputy Attorney General
Attorneys for Complainant

LA2015603837
52431394.docx

Exhibit A

Accusation No. 5622

1 KAMALA D. HARRIS
Attorney General of California
2 THOMAS L. RINALDI
Supervising Deputy Attorney General
3 GEOFFREY WARD
Deputy Attorney General
4 State Bar No. 246437
300 So. Spring Street, Suite 1702
5 Los Angeles, CA 90013
Telephone: (213) 897-2660
6 Facsimile: (213) 897-2804
E-mail: Geoffrey.Ward@doj.ca.gov
7 *Attorneys for Complainant*

8 **BEFORE THE**
9 **BOARD OF PHARMACY**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

11 In the Matter of the Accusation Against:

12 **UNICARE PHARMACY, INC. DBA**
13 **MEDICORX SPECIALTY**
7039 Valjean Avenue
Van Nuys, CA 91406

Case No. 5622

ACCUSATION

14 **Original Permit No. PHY 50336,**

15 **VLADIMIR LENCHITSKY**
3514 Cody Road
16 Sherman Oaks, CA 91403

17 **Pharmacist License No. RPH 51484,**

18 **and**

19 **MICHAEL J. STERLING**
7039 Valjean Avenue
20 Van Nuys, CA 91406

21 **Pharmacist License No. RPH 36628**

22 Respondents.

24 Complainant alleges:

25 **PARTIES**

26 1. Complainant Virginia Herold brings this Accusation solely in her official capacity as
27 the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.

1 shall be final, except that the propriety of the action is subject to review by the
2 superior court pursuant to Section 1094.5 of the Code of Civil Procedure.

3 BUSINESS AND PROFESSIONS CODE STATUTES

4 7. Section 4022 defines dangerous drugs:

5 'Dangerous drug' or 'dangerous device' means any drug or device unsafe for self-use in
6 humans or animals, and includes the following:

7 (a) Any drug that bears the legend: "Caution: federal law prohibits
8 dispensing without prescription," "Rx only," or words of similar import.

9 (b) Any device that bears the statement: "Caution: federal law restricts this
10 device to sale by or on the order of a _____," "Rx only," or words of similar
11 import, the blank to be filled in with the designation of the practitioner licensed to use
12 or order use of the device.

13 (c) Any other drug or device that by federal or state law can be lawfully
14 dispensed only on prescription or furnished pursuant to Section 4006.

15 8. Section 4036.5 defines "pharmacist-in-charge":

16 Pharmacist-in-charge" means a pharmacist proposed by a pharmacy and approved
17 by the board as the supervisor or manager responsible for ensuring the pharmacy's
18 compliance with all state and federal laws and regulations pertaining to the practice of
19 pharmacy.

20 9. Section 4076 mandates proper labeling:

21 (a) A pharmacist shall not dispense any prescription except in a container
22 that meets the requirements of state and federal law and is correctly labeled with all of
23 the following:

24 (1) Except where the prescriber or the certified nurse-midwife who
25 functions pursuant to a standardized procedure or protocol described in Section
26 2746.51, the nurse practitioner who functions pursuant to a standardized procedure
27 described in Section 2836.1, or protocol, or the physician assistant who functions
28 pursuant to Section 3502.1, the naturopathic doctor who functions pursuant to a
standardized procedure or protocol described in Section 3640.5, or the pharmacist
who functions pursuant to a policy, procedure, or protocol pursuant to either
subparagraph (D) of paragraph (4) of, or clause (iv) of subparagraph (A) of paragraph
(5) of, subdivision (a) of Section 4052 orders otherwise, either the manufacturer's
trade name of the drug or the generic name and the name of the manufacturer.
Commonly used abbreviations may be used. Preparations containing two or more
active ingredients may be identified by the manufacturer's trade name or the commonly
used name or the principal active ingredients.

(2) The directions for the use of the drug.

(3) The name of the patient or patients.

(4) The name of the prescriber or, if applicable, the name of certified
nurse-midwife who functions pursuant to a standardized procedure or protocol
described in Section 2746.51, the nurse practitioner who functions pursuant to a
standardized procedure described in Section 2836.1, or protocol, the physician
assistant who functions pursuant to Section 3502.1., the naturopathic doctor who

1 functions pursuant to a standardized procedure or protocol described in Section
2 3640.5, or the pharmacist who functions pursuant to a policy, procedure, or protocol
3 pursuant to either subparagraph (D) of paragraph (4) of, or clause (iv) of
4 subparagraph (A) of paragraph (5) of, subdivision (a) of Section 4052.

5 (5) The date of issue.

6 (6) The name and address of the pharmacy, and prescription number or
7 other means of identifying the prescription.

8 (7) The strength of the drug or drugs dispensed.

9 (8) The quantity of the drug or drugs dispensed.

10 (9) The expiration date of the effectiveness of the drug dispensed.

11 (10) The condition for which the drug was prescribed if requested by the
12 patient and the condition is indicated on the prescription.

13 (11)(A) Commencing January 1, 2006, the physical description of the
14 dispensed medication, including its color, shape, and any identification code that
15 appears on the tablets or capsules, except as follows:

16 (i) Prescriptions dispensed by a veterinarian.

17 (ii) An exemption from the requirements of this paragraph shall be
18 granted to a new drug for the first 120 days that the drug is on the market and for the
19 90 days during which the national reference file has no description on file.

20 (iii) Dispensed medications for which no physical description exists in
21 any commercially available database.

22 (B) This paragraph applies to outpatient pharmacies only.

23 (C) The information required by this paragraph may be printed on an
24 auxiliary label that is affixed to the prescription container.

25 (D) This paragraph shall not become operative if the board, prior to
26 January 1, 2006, adopts regulations that mandate the same labeling requirements set
27 forth in this paragraph.

28 (b) If a pharmacist dispenses a prescribed drug by means of a unit dose
medication system, as defined by administrative regulation, for a patient in a skilled
nursing, intermediate care, or other health care facility, the requirements of this section
will be satisfied if the unit dose medication system contains the aforementioned
information or the information is otherwise readily available at the time of drug
administration.

(c) If a pharmacist dispenses a dangerous drug or device in a facility
licensed pursuant to Section 1250 of the Health and Safety Code, it is not necessary to
include on individual unit dose containers for a specific patient, the name of the
certified nurse-midwife who functions pursuant to a standardized procedure or
protocol described in Section 2746.51, the nurse practitioner who functions pursuant
to a standardized procedure described in Section 2836.1, the physician assistant who
functions pursuant to Section 3502.1, the naturopathic doctor who functions pursuant
to a standardized procedure or protocol described in Section 3640.5, or the pharmacist
who functions pursuant to a policy, procedure, or protocol pursuant to either
subparagraph (D) of paragraph (4) of, or clause (iv) of subparagraph (A) of paragraph
(5) of, subdivision (a) of Section 4052,

(d) If a pharmacist dispenses a prescription drug for use in a facility
licensed pursuant to Section 1250 of the Health and Safety Code, it is not necessary to
include the information required in paragraph (11) of subdivision (a) when the
prescription drug is administered to a patient by a person licensed under the Medical

1 Practice Act (Chapter 5 (commencing with Section 2000), the Nursing Practice Act
2 (Chapter 6 (commencing with Section 2700), or the Vocational Nursing Act (Chapter
3 6.5 (commencing with Section 2840), who is acting within his or her scope of
4 practice."

5 10. Section 4077 states, in pertinent part, that except as provided in subdivisions (b) and
6 (c) of this section, no person shall dispense any dangerous drug upon prescription except in a
7 container correctly labeled with the information required by Section 4076.

8 11. In relevant part, section 4301 authorizes disciplinary action for certain misconduct:

9 The board shall take action against any holder of a license who is guilty of
10 unprofessional conduct or whose license has been procured by fraud or
11 misrepresentation or issued by mistake. Unprofessional conduct shall include, but is
12 not limited to, any of the following:

13 ...

14 (j) The violation of any of the statutes of this state, of any other state, or
15 of the United States regulating controlled substances and dangerous drugs.

16 ...

17 (o) Violating or attempting to violate, directly or indirectly, or assisting in
18 or abetting the violation of or conspiring to violate any provision or term of this
19 chapter or of the applicable federal and state laws and regulations governing
20 pharmacy, including regulations established by the board or by any other state or
21 federal regulatory agency.

22 HEALTH AND SAFETY CODE STATUTES

23 12. In relevant part, section 4169 imposes restrictions on the selling of misbranded
24 dangerous drugs:

25 (a) A person or entity shall not do any of the following:

26 ...

27 (3) Purchase, trade, sell, or transfer dangerous drugs that the
28 person knew or reasonably should have known were misbranded, as defined
in Section 111335 of the Health and Safety Code.

13. Health and Safety Code section 111340 is one of several statutes specifying when a
drug is misbranded:

Any drug or device is misbranded unless it bears a label containing all of
the following information:

(a) The name and place of business of the manufacturer, packer, or
distributor.

(b) An accurate statement of the quantity of the contents in terms of
weight, measure, or numerical count.

1 Reasonable variations from the requirements of subdivision (b) shall be
2 permitted. Requirements for placement and prominence of the information and
3 exemptions as to small packages shall be established in accordance with regulations
4 adopted pursuant to Section 110380.

5 14. Health and Safety Code section 111440 provides "[i]t is unlawful for any person to
6 manufacture, sell, deliver, hold, or offer for sale any drug or device that is misbranded."

7 **BOARD OF PHARMACY REGULATIONS**

8 15. California Code of Regulations, title 16, section 1717, sets standards for pharmacy
9 practice:

10 (a) No medication shall be dispensed on prescription except in a new
11 container which conforms with standards established in the official compendia.

12 Notwithstanding the above, a pharmacist may dispense and refill a
13 prescription for non-liquid oral products in a clean multiple-drug patient medication
14 package (patient med pak), provided:

15 (1) a patient med pak is reused only for the same patient;

16 (2) no more than a one-month supply is dispensed at one time; and

17 (3) each patient med pak bears an auxiliary label which reads, store in a
18 cool, dry place.

19 (b) In addition to the requirements of Section 4040, Business and
20 Professions Code, the following information shall be maintained for each prescription
21 on file and shall be readily retrievable:

22 (1) The date dispensed, and the name or initials of the dispensing
23 pharmacist. All prescriptions filled or refilled by an intern pharmacist must also be
24 initialed by the supervising pharmacist before they are dispensed.

25 (2) The brand name of the drug or device; or if a generic drug or device is
26 dispensed, the distributor's name which appears on the commercial package label; and

27 (3) If a prescription for a drug or device is refilled, a record of each refill,
28 quantity dispensed, if different, and the initials or name of the dispensing pharmacist.

(4) A new prescription must be created if there is a change in the drug,
strength, prescriber or directions for use, unless a complete record of all such changes
is otherwise maintained.

(c) Promptly upon receipt of an orally transmitted prescription, the
pharmacist shall reduce it to writing, and initial it, and identify it as an orally
transmitted prescription. If the prescription is then dispensed by another pharmacist,
the dispensing pharmacist shall also initial the prescription to identify him or herself.

All orally transmitted prescriptions shall be received and transcribed by a
pharmacist prior to compounding, filling, dispensing, or furnishing.

Chart orders as defined in Section 4019 of the Business and Professions
Code are not subject to the provisions of this subsection.

(d) A pharmacist may furnish a drug or device pursuant to a written or
oral order from a prescriber licensed in a State other than California in accordance
with Business and Professions Code Section 4005.

(e) A pharmacist may transfer a prescription for Schedule III, IV, or V

1 controlled substances to another pharmacy for refill purposes in accordance with Title
2 21, Code of Federal Regulations, section 1306.26.

3 Prescriptions for other dangerous drugs which are not controlled
4 substances may also be transferred by direct communication between pharmacists or
5 by the receiving pharmacist's access to prescriptions or electronic files that have been
6 created or verified by a pharmacist at the transferring pharmacy. The receiving
7 pharmacist shall create a written prescription; identifying it as a transferred
8 prescription; and record the date of transfer and the original prescription number.
9 When a prescription transfer is accomplished via direct access by the receiving
10 pharmacist, the receiving pharmacist shall notify the transferring pharmacy of the
11 transfer. A pharmacist at the transferring pharmacy shall then assure that there is a
12 record of the prescription as having been transferred, and the date of transfer. Each
13 pharmacy shall maintain inventory accountability and pharmacist accountability and
14 dispense in accordance with the provisions of section 1716 of this Division.
15 Information maintained by each pharmacy shall at least include:

16 (1) Identification of pharmacist(s) transferring information;

17 (2) Name and identification code or address of the pharmacy from which
18 the prescription was received or to which the prescription was transferred, as
19 appropriate;

20 (3) Original date and last dispensing date;

21 (4) Number of refills and date originally authorized;

22 (5) Number of refills remaining but not dispensed;

23 (6) Number of refills transferred.

24 (f) The pharmacy must have written procedures that identify each
25 individual pharmacist responsible for the filling of a prescription and a corresponding
26 entry of information into an automated data processing system, or a manual record
27 system, and the pharmacist shall create in his/her handwriting or through
28 hand-initializing a record of such filling, not later than the beginning of the pharmacy's
next operating day. Such record shall be maintained for at least three years.

COST RECOVERY

16. Section 125.3 authorizes the Board to ask an administrative law judge to direct
licensees found to have violated licensing acts to pay their case's reasonable investigation and
enforcement costs.

CAUSE FOR DISCIPLINE

(Against All Respondents)

(Misbranded Medications)

17. Respondents Unicare Pharmacy, Inc., Michael Sterling, and Vladimir Lenchitsky are
subject to disciplinary action under section 4301 subdivision (o) for violating Health and Safety
Code section 111440 in conjunction with Health and Safety Code section 111340 subdivision (b)
by holding numerous misbranded drugs at the pharmacy.

1 18. Complainant realleges paragraphs 2 through 4.

2 19. On March 10 and March 11, 2015, Board investigators inspected Unicare Pharmacy,
3 Inc.'s pharmacy at 7039 Valjean Avenue in Van Nuys, California.

4 20. During their inspection, on the pharmacy's shelves they found medication stock bottles
5 with more pills than their labels indicated.

6 21. When asked about this, Vladimir Lenchitsky explained that on occasion pharmacy
7 technicians would combine bottles of the same medication, strength, manufacturer, lot number and
8 expiration date to manage large number of bottles accumulated on the active medication shelves.

9 22. The table below, with one exception, shows the medication stock bottles the
10 inspectors found at the pharmacy that contained more tablets or capsules than they should have.
11 All of the medications listed are dangerous drugs under Business and Professions Code section
12 4022 because they can be dispensed only with a prescription. None of them are controlled
13 substances. Each of these were found in their original manufacturer's container.

Brand Name	Generic Name	Quantity in Original Manufacturer's Container	Quantity Found at Pharmacy
Plavix 75mg	clopidogrel	90 tablets	125 tablets
Fanapt 2mg	iloperidone	60 tablets	75 tablets
Cymbalta 60mg	duloxetine	30 capsules	57 tablets
Rapaflo 4mg	silodosin	30 capsules	109 capsules
Tindamax 500 mg	tinidazole	20 tablets	43 tablets
Dexilant 30mg	dexlansoprazole	30 capsules	44 capsules
Abilify 15mg	aripiprazole	30 tablets	29 half-tablets
Cymbalta 60mg	duloxetine	30 capsules	54 capsules
Geodon 80mg	ziprasidone	60 capsules	88 capsules
Geodon 60mg	ziprasidone	60 capsules	93 capsules
Dexilant 30mg	dexlansoprazole	30 capsules	52 capsules
Januvia 100mg	sitagliptin	90 tablets	53 whole tablets and 64 half-tablets
Diovan HCT 80/12.5mg	valsartan/hetz	90 tablets	165 tablets

1	Fanapt 10mg	iloperidone	60 tablets	79 tablets
2	Coumadin 7.5mg	warfarin	100 tablets	152 tablets
3	Brintellix 5mg	vortioxetine	30 tablets	76 tablets
4	Latuda 40mg	lurasidone	30 tablets	85 tablets
5	Benicar 5mg	olmesartan	30 tablets	64 tablets
6	Geodon 80mg	ziprasidone	60 capsules	66 capsules
7	Geodon 20mg	ziprasidone	60 capsules	99 capsules
8	Aricept 23mg	donepezil	30 tablets	118 tablets
9	Sensipar 90mg	cinacalcet	30 tablets	60 tablets
10	Prandin 2mg	repaglinide	100 tablets	186 tablets
11	Prandin 1mg	repaglinide	100 tablets	110 tablets

12 23. As noted in the table, the bottles of Ability and Januvia contained half-tablets, tablets
13 that someone had cut in half.

14 24. In addition, the inspectors found a bottle of the brand name drug Zocor, whose
15 generic name is simvastatin, that was not in the original manufacturer's bottle, but instead was in a
16 bottle with another pharmacy's label upon it.

17 25. The bottles listed in the table did not have an accurate statement of the quantity of
18 their contents in terms of numerical count, in violation of Health and Safety Code section 111340
19 subdivision (b).

20 26. The bottles of Ability and Januvia that contained half-tablets also did not have an
21 accurate statement of the weight of those half-tablets, also in violation of Health and Safety Code
22 section 111340 subdivision (b).

23 27. The pharmacy's variations from the requirements of section 111340 subdivision (b)
24 were not reasonable.

25 28. Respondent Vladimir Lenchitsky was aware of or participated in the stocking of these
26 medications.

27 29. Respondent Michael Sterling was aware of the stocking of these medications.
28 Furthermore, as the pharmacist-in-charge he is strictly or vicariously liable or both for the actions
of the pharmacy or its pharmacists or pharmacy technicians.

///

1 DISCIPLINARY CONSIDERATIONS

2 30. To determine the degree of discipline, if any, to be imposed on Respondent Vladimir
3 Lenchitsky, Complainant alleges that on or about August 23, 2012, in a prior action, the Board of
4 Pharmacy issued Citation Number CI 2012 53625 fining Mr. Lenchitsky \$1,000 for failing to
5 maintain accurate records of schedule II controlled substance prescriptions, for failing to label drug
6 canisters with the expiration date of the drug inside, and for failing to keep records of the date or
7 quantity of schedule II controlled substances received. That Citation is now final and is
8 incorporated by reference as if fully set forth.

9 31. To determine the degree of discipline, if any, to be imposed on Respondent Vladimir
10 Lenchitsky, Complainant alleges that on or about July 1, 2013, in a prior action, the Board of
11 Pharmacy issued Citation Number CI 2012 55139 fining Mr. Lenchitsky \$1,000 for a May 2013
12 driving under the influence conviction. That Citation is now final and is incorporated by reference
13 as if fully set forth.

14 32. To determine the degree of discipline, if any, to be imposed on Respondent Michael J.
15 Sterling, Complainant alleges that on or about June 7, 2014, in a prior action, the Board of
16 Pharmacy issued Citation Number CI 2013 62487 fining Mr. Sterling \$750 for incorrectly
17 dispensing the wrong medication to a patient. That Citation is now final and is incorporated by
18 reference as if fully set forth.

19 PRAYER

20 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
21 and that following the hearing, the Board of Pharmacy issue a decision:

- 22 1. Revoking or suspending Original Permit Number PHY 50336, issued to Unicare
23 Pharmacy, Inc. dba Medicorx Specialty;
- 24 2. Revoking or suspending Pharmacist License Number RPH 51484, issued to Vladimir
25 Lenchitsky;
- 26 3. Revoking or suspending Pharmacist License Number RPH 36628, issued to Michael J.
27 Sterling;

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

4. Ordering Medicorx Specialty, Vladimir Lenchitsky and Michael J. Sterling to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3; and

5. Taking such other and further action as deemed necessary and proper.

DATED: 3/11/16

Virginia Herold

VIRGINIA HEROLD
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant

LA2015603837
61845292_3.doc

Exhibit B

Letter of Public Reproval in Case No. 5622

Date: _____

Vladimer Lenchitsky
3514 Cody Road
Sherman Oaks, CA 91403

Michael J. Sterling
7 Hacienda Road
Bell Canyon, CA 91307

Re: LETTER OF PUBLIC REPROVAL
In the Matter of the Accusation Against:
Unicare Pharmacy, Inc. dba Medicorx Specialty, Original Permit No. PHY 50336,
Vladimer Lenchitsky, Pharmacist License No. RPH 51484, and Michael J. Sterling,
Pharmacist License No. RPH 36628, Respondents
Board of Pharmacy Case No. 5622

Dear Mr. Lenchitsky and Mr. Sterling:

On March 11, 2016, the California State Board of Pharmacy, Department of Consumer Affairs, filed an Accusation against the pharmacy permit issued to Unicare Pharmacy, Inc., dba MedicoRx Speciality ("Unicare") and the pharmacist licenses issued to Vladimer Lenchitsky ("Lenchitsky") and Michael J. Sterling ("Sterling"). The Accusation alleged that the licensees are subject to discipline under Business & Professions Code section 4301, subdivision (o), for violations of state law that were discovered during an inspection conducted on March 10 and 11, 2015, including Health & Safety Code section 111440 [misbranding] in conjunction with Health & Safety Code section 111340, subdivision (b) [acts constituting misbranding]. You have chosen not to contest these violations for the purpose of settlement.

Acts of misbranding are serious violations of the law. However, taking into account your lack of prior disciplinary history, the Board has decided that the charges warrant a public reproof.

Accordingly, in resolution of this matter under the authority provided under Business & Professions Code section 495, the Board of Pharmacy, Department of Consumer Affairs, issues this letter of public reproof. You have waived any right to contest or appeal this letter, and it is final as of the date of issuance. This letter constitutes license discipline.

Sincerely,

VIRGINIA HEROLD
Executive Officer
Board of Pharmacy
Department of Consumer Affairs